Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Deal Watch

- PMLiVE

Healthcare sector bullish despite political uncertainty

Targeted and gene therapies rated as major advances ahead of Jefferies conference in London

- PMLiVE

Decision time for Brexit

Pharma fears a no deal Brexit - but compromise deal has opponents on both sides

- PMLiVE

Brexit to blame as firm plans to leave UK for Ireland

Tax-inversion deal brought company to UK - now Brexit causes a re-think

- PMLiVE

Gilead NASH drug clears mid-stage trial, but rivals are looming

Positive results to challenge Intercept in emerging disease area

- PMLiVE

GSK among businesses wooed as Brexit reckoning nears

Emma Walmsley to co-chair panel with supermarket CEO

- PMLiVE

Brexit: can pharma ‘take back control’ of the narrative?

Four Public Affairs managing director Sarah Jones talks to PME about the risks of Brexit - and how the sector musn't let the long-term issues become obscured

- PMLiVE

Warning ‘at red’ on no deal Brexit medicines chaos

Report says it's already too late to prepare for a no deal scenario

- PMLiVE

Novartis and Pfizer to collaborate on NASH combinations

Big pharma giants target nascent multi-billion market

- PMLiVE

Budget 2018: UK life sciences sector delivers its verdict

UK Chancellor Philip Hammond delivered a budget that was broadly pro-business but contained mixed news for the life sciences industry, according to two industry bodies.The headline news of an additional...

- PMLiVE

UK science could be ‘crippled’ by a hard Brexit

Francis Crick Institute scientists more likely to leave UK post-Brexit

- PMLiVE

AZ says UK investments on hold until there is Brexit ‘clarity’

Tomorrow's EU summit could be make-or-break for Brexit deal

- PMLiVE

UK pharma leader warns on ‘untenable’ Brexit deal

Draft agreement is a major step back for UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links